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Objective: Atrial ﬁbrillation is the most common sustained arrhythmia in patients with
rheumatic heart disease (RHD). This study was conducted to determine the maintenance of
sinus rhythm with amiodarone therapy following DC cardioversion (DCCV), early after
successful balloon mitral valvuloplasty (BMV).
Methods: Patients were randomized to amiodarone group and placebo group and their
baseline characteristics were recorded. DCCV was done 48 h after BMV. After cardioversion,
oral amiodarone was started initially 200 mg three times a day for 2 weeks, then 200 mg
twice daily for two weeks followed by 200 mg once daily for 12 months. Patients in placebo
group received DCCV alone without preloading amiodarone. After DCCV, they were given
placebo for 12 months.
Results: The 3 months follow-up period was completed by 77 patients (95%). Of them, 31
(77.5%) patients in amiodarone group and 14 (34.1%) in placebo group remained in sinus
rhythm (SR). The 12 months follow-up period was completed by 73 patients (90.1%). Of them,
22 (55%) patients in amiodarone group and 7 (17.1%) in placebo group remained in SR.
Conclusion: We conclude that amiodarone is more effective than placebo in maintenance of
SR at the end of 3 months following successful cardioversion and more patients continued to
remain in SR even at the end of 12 months without major serious adverse effects.
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open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Atrial ﬁbrillation (AF) is common in patients with rheumatic
valvular heart disease.1 Strategies to maintain sinus rhythm
(SR) in nonvalvular AF have been shown to improve functional
capacity and quality of life (QoL).2–4 The failure to reduce the
mortality associated with rhythm-control strategies is in part
due to the toxicity of the therapies used to maintain SR5
Attempts to restore SR in rheumatic mitral stenosis (MS) have
been rare because the long duration of AF and left atrial (LA)
enlargement does not bode well for maintenance of normal
SR.6–9 Successful balloon mitral valvuloplasty (BMV) in MS by
reducing LA pressure and chronic atrial stretch has been
reported to result in a favorable reversal of electrical remodeling
and reduced AF vulnerability.10 Electrical DC cardioversion
(DCCV) following successful BMV may lead to a better chance of
successful cardioversion and a better chance of maintaining
SR.11 Large et al. demonstrated that surgical correction of mitral
valve disease in patients who have AF resulted in spontaneous
conversion to SR in 46%.12,13 However, the rate of spontaneous
conversion was much lower in other reports.8
In rheumatic MS after BMV, DCCV combined with amio-
darone therapy successfully restored SR and maintained it in
49–81% patients at a mean follow-up of 18–31 months,7,8 a
success rate apparently surpassing that achieved by catheter-
based radiofrequency ablation in this particular group of
patients.14,15 Amiodarone is preferred as the antiarrhythmic
drug because it has been reported to be more effective than
sotalol or class I agents for maintenance of SR in AF11 and is
particularly effective in rheumatic AF patients after mitral
valve surgery6 or BMV.7,8
The primary objectives of this study were to determine the
maintenance rate of SR at 3 months and 12 months following
amiodarone therapy and to assess the improvement in QoL
by maintaining SR and also to determine the success rate of
DCCV early after successful BMV in patients with symptomatic
rheumatic MS with persistent AF.
2. Material and methods
2.1. Study population
From August 2010 to May 2012, we studied 89 patients with
rheumatic MS with persistent AF without signiﬁcant other
valvular heart disease who underwent successful BMV. The
duration of AF varied from 3 months to more than 2 years. In
all patients, transthoracic echocardiographic examinations
were performed to measure mitral valve area, mitral pressure
gradient; LA diameter and LA pressure gradient were recorded
immediately before and 24 h after BMV. LA diameter was
measured during the diastolic phase using M-Mode study in
the parasternal long axis view. LA pressure and mitral gradient
were recorded in catheterization lab before and after BMV.
2.1.1. Inclusion criteria
Patients over 18 years of age who underwent successful BMV
and Electrocardiogram (ECG) evidence of AF for more than
3 months.2.1.2. Exclusion criteria
Prior history of cardioversion, signiﬁcant mitral, tricuspid or
aortic regurgitation, signiﬁcant tricuspid and aortic stenosis,
LA thrombus (detected by transesophageal echocardiography),
LA diameter ≥6 cm, inability to comply with 12 months follow-
up period or contraindications to anticoagulation and amio-
darone. BMV was performed using accura balloon and the
transseptal approach.
2.2. Study protocol
All eligible patients provided informed written consent before
participation and all procedures followed institutional ethical
standards and guidelines. The study complies with Declara-
tion of Helsinki.
Patients were anticoagulated with warfarin and Interna-
tional normalized ratio was required to be between 2 and 3 for
at least one month prior to DCCV. Patients were randomized to
amiodarone group and placebo group and their baseline
characteristics were recorded. DCCV was done 48 h after BMV.
All of them were kept fasting through the night before they
underwent cardioversion.
Patients in the amiodarone group were given amiodarone
IV bolus 150 mg followed by 1 g IV infusion for 12 h prior to
DCCV. After cardioversion, oral amiodarone was started
initially 200 mg three times a day for 2 weeks, then 200 mg
twice daily for two weeks followed by 200 mg once daily for
12 months.
Patients in placebo group received DCCV alone without
preloading amiodarone. After DCCV, they were given placebo
for 12 months.
Before DCCV, patients were administered IV midazolam or
diazepam for sedation and meperidine for analgesia. Syn-
chronized DCCV was given using biphasic deﬁbrillators using
the following protocol: 100 J, 200 J, 300 J, and 360 J. Unsuccess-
ful DCCV was considered to include those who did not revert
with 360 J.
2.3. Follow-up and assessment
Patients were followed up at 1, 3, 6, 9, and 12 months. During
the visits, cardiac rhythm was determined by ECG. QoL was
assessed using SF8 questionnaire. The physical component
scores (PCS8) as well as the mental component scores (MCS8)
were assessed separately. Patients under amiodarone group
were assessed for drug side effects and drug interaction. All
patients continued to take oral anticoagulants throughout the
study period irrespective of their rhythm.
2.4. Endpoints of the study
The primary endpoint was the comparison of amiodarone
versus placebo in maintaining SR at 3 and 12 months following
successful cardioversion in patients with rheumatic MS with
persistent AF undergoing BMV. The secondary endpoints were
to identify the success rate of cardioversion following
successful BMV, to identify the success rate of IV amiodarone
in converting AF to SR, to identify the factors affecting
maintenance of SR, changes in the QoL scores at follow-up
and frequency of adverse events.
Table 1 – Baseline clinical and ECG parameters in
amiodarone and placebo group.
Parameters Amiodarone
group
(n = 44)
Placebo
group
(n = 45)
p value
Demographic parameters
Age (mean  SD,
years)
38.80  8.426 37.62  9.260 0.534
Male, % 20.5% 34.1% 0.151
Female, % 79.5% 65.9% 0.853
Duration of AF
(mean  SD,
months)
10.05  5.718 10.27  5.495
PCS 8 (mean  SD) 48.03  5.005 46.46  4.628 0.126
MCS 8 (mean  SD) 45.08  4.928 43.94  5.276 0.297
Pre-BMV echocardiographic parameters
MVA (mean  SD,
cm2)
0.873  0.178 0.876  0.188 0.942
MVG (mean  SD,
mmHg)
21.25  4.457 22.49  3.758 0.159
LA size (mean  SD,
cm)
4.918  0.436 4.920  0.430 0.984
LA pressure
(mean  SD, mmHg)
27.11  4.909 28.29  4.966 0.265
PASP (mean  SD,
mmHg)
60.80  12.08 64.96  14.44 0.144
Other valve disease
Mild AR, % 13.6% 13.3% 0.684
Moderate AR, % 11.4% 15.6%
Mild AS, % 18.2% 15.6%
Moderate AS, % 2.3% 8.9%
Mild AR and AS, % 0.0% 2.2%
None, % 54.5% 44.4%
Other medical illness
None, % 86.4% 86.7% 0.999
Hypertension, % 4.5% 6.7%
Diabetes, % 4.5% 2.2%
Hypertension and
diabetes, %
2.3% 4.4%
Diabetes and
coronary heart
disease, %
2.3% 0.0%
NYHA class I, % 20.5% 4.4% 0.999
NYHA class II, % 63.6% 75.6%
NYHA class III, % 11.4% 13.3%
NYHA class IV, % 4.5% 6.7%
Concomitant drugs
Beta blockers, % 48.9% 43.2% 0.672
Calcium channel
blockers, %
24.4% 22.7% 1.000
Digoxin, % 64.4% 68.2% 0.823
AF – atrial ﬁbrillation; PCS8 – physical component scores; MCS8 –
mental component scores; MVA – mitral valve area; MVG – mitral
valve gradient; LA – left atrium; PASP – pulmonary artery systolic
pressure; AR – aortic regurgitation; AS – aortic stenosis; NYHA –
New York Heart Association.
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All statistical analyses were performed using SPSS version
17.0. Continuous variables are presented as mean  SDs and
categorical variables were described with frequencies and
percentages. The comparison of continuous variables was
performed by independent sample t test. The categorical
variables were compared using chi-square test or ﬁsher's exact
test. Signiﬁcance was assumed if p < 0.05. The predictors
of maintenance of SR at 3 and 12 months and predictors of
successful cardioversion were assessed by univariate analysis.
Kaplan–Meier analysis was performed for analysis of proba-
bility of freedom from AF between patients in amiodarone and
placebo group. The difference between these two groups was
compared by the log-rank test.
3. Results
Forty-eight hours following successful BMV, 89 patients with
rheumatic MS with persistent AF were included for the study.
They were randomized to amiodarone (n = 44) and placebo
group (n = 45). The baseline characteristics (Table 1) were
equally distributed between amiodarone and placebo group.
3.1. Outcomes of cardioversion
Cardioversion was successful in 81 patients (91%) and failed in
8 (9%) patients. 100 J energy was used in 53 (65.4%), 200 J in 22
(27.2%) and 300 J in 6 (7.4%). 6 (7.4%) patients developed marked
bradycardia after conversion to SR and they recovered
spontaneously after 6 h. There was no signiﬁcant difference
in the success rate of DCCV between amiodarone and placebo
group (p = 0.974). Of the 44 patients who received pretreatment
with IV amiodarone, SR was not restored in any patient with IV
amiodarone alone. 4 patients (9.1%) in this group developed
signiﬁcant bradycardia. No other complications were encoun-
tered (Table 2).
3.2. Cardiac rhythms during 3 months follow-up
The 3 months follow-up period was completed by 77 patients
(95%). Four patients were lost to follow-up after the ﬁrst month
visit. Of the 40 patients in amiodarone group and 41 patients in
placebo group, 38 and 39 patients completed 3 months follow-
up respectively. Of them, 31 (77.5%) patients in amiodarone
group and 14 (34.1%) in placebo group remained in SR. Table 3
shows amiodarone to be superior in maintaining SR at the end of
3 months (p < 0.001) than placebo. The PCS8 and MCS8 scores at
the end of 3 months were found to be signiﬁcantly better in
amiodarone group (p = 0.039 and 0.023, respectively) (Table 4).
The Kaplan–Meier analysis (Fig. 1) revealed signiﬁcant
difference in the probability of freedom from AF between
patients in amiodarone and placebo groups ( p < 0.001 in log-
rank test); of the 45 patients who remained in SR in both the
groups, univariate analysis of the possible factors that might
inﬂuence the probability of AF recurrence (Table 5). The LA
diameter was the only factor that signiﬁcantly determined the
cardiac rhythm at 3 months (p = 0.047) on logistic regression
analysis. Of those who remained in SR, the PCS8 and MCS8scores were signiﬁcantly better (p < 0.001 and p < 0.001,
respectively) than those who were in AF (Table 6).
3.3. Cardiac rhythms during 12 months follow-up
The 12 months follow-up period was completed by 73 (90.1%)
patients. Four patients were lost to follow-up after 3 months.
Thirty-six patients in amiodarone group and 37 patients in
Table 4 – Univariate analysis of parameters for remaining
in SR at 3 months.
Factors Rhythm at 3 months p
value
Sinus
rhythm
Atrial
ﬁbrillation
Age (mean  SD,
years)
38.09  8.279 39.81  9.683 0.404
Duration of AF
(mean  SD, months)
8.40  4.520 10.03  5.313 0.151
Pre-MVA (mean  SD,
cm2)
0.89  0.182 0.88  0.170 0.695
Pre-MVG (mean  SD,
mmHg)
21.49  4.531 22.38  3.508 0.357
Pre-LA size (mean  SD,
cm)
4.78  0.416 4.96  0.354 0.047
Pre-LA pressure
(mean  SD, mmHg)
27.38  4.692 28.69  5.127 0.249
Pre-PASP (mean  SD,
mmHg)
60.73  12.86 64.44  14.91 0.247
AF – atrial ﬁbrillation; MVA – mitral valve area; MVG – mitral valve
gradient; LA – left atrium; PASP – pulmonary artery systolic
pressure.
Table 2 – Rhythm pattern at 3rd and 12th months in
amiodarone vs placebo group.
Rhythm Group p value
Amiodarone,
n (%)
Placebo,
n (%)
3rd month Sinus rhythm 31 (77.5%) 14 (34.1%) <0.001
Atrial
ﬁbrillation
7 (17.5%) 25 (61.0%)
12th month Sinus rhythm 22 (55.0%) 7 (17.1%) 0.001
Atrial
ﬁbrillation
14 (35.0%) 30 (73.2%)
Table 3 – QoL scores and NYHA functional class between
both groups during follow-up at 3 months.
Factors Amiodarone
group
(mean SD)
Placebo
group
(mean SD)
p
value
PCS8 at 3 months 49.72  6.522 46.82  5.594 0.039
MCS8 at 3 months 53.43  6.529 50.32  5.152 0.023
PCS8 at 12 months 49.79  6.794 46.62  5.917 0.037
MCS8 at 12 months 53.89  6.244 50.15  5.216 0.007
PCS8 – physical component scores; MCS8 – mental component
scores.
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(55%) patients in amiodarone group and 7(17.1%) in placebo
group remained in SR. Amiodarone was found to be superior in
maintaining SR at the end of 12 months (p = 0.001), as shown inFig. 1 – Kaplan–Meier analysis showing the probability of freedo
group patients.Table 3 and Fig. 1. The PCS8 and MCS8 scores at the end of
12 months were found to be signiﬁcantly better in amiodarone
group (p = 0.037 and 0.007, respectively) (Table 6).
Of the 29 patients who remained in SR in both the groups,
univariate analysis of the possible factors that might inﬂuencem from atrial fibrillation between amiodarone and placebo
Table 5 – QoL scores and functional NYHA class in
patients with SR at 3 months.
Factors at
3 months
Rhythm at 3 months p value
Sinus rhythm Atrial
ﬁbrillation
PCS8 (mean  SD) 50.92  5.594 44.50  5.006 <0.001
MCS8 (mean  SD) 54.92  5.273 47.55  4.141 <0.001
NYHA I, % 48.9% 21.9% 0.022
NYHA II, % 50.1% 75%
NYHA III, % 0% 3.1%
PCS8 – physical component scores; MCS8 – mental component
scores; NYHA – New York Heart Association.
Table 7 – QoL scores and functional NYHA class in
patients with SR at 12 months.
Factors at
12 months
Rhythm at 12 months p value
Sinus rhythm Atrial
ﬁbrillation
PCS8 (mean  SD) 53.59  4.345 44.98  4.942 <0.001
MCS8 (mean  SD) 57.12  3.824 48.82  4.818 <0.001
NYHA I, % 51.7% 31.8% 0.174
NYHA II, % 48.3% 65.9%
NYHA III, % 0% 2.3%
PCS8 – physical component scores; MCS8 – mental component
scores; NYHA – New York Heart Association.
Table 8 – Pre- vs post-BMV results.
Factors Pre-BMV Post-BMV p value
MVA (mean  SD,
cm2)
0.87  0.183 1.81  0.231 <0.001
MVG (mean  SD,
mmHg)
21.88  4.142 11.82  4.122 <0.001
LA size (mean  SD,
cm)
4.92  0.431 4.63  0.453 <0.001
LA pressure
(mean  SD,
mmHg)
27.71  4.946 14.46  4.734 <0.001
PASP (mean  SD,
mmHg)
62.90  13.415 39.16  11.590 <0.001
EF (mean  SD, %) 58.06  3.472 59.39  2.859 <0.001
MVA – mitral valve area; MVG – mitral valve gradient; LA – left
atrium; PASP – pulmonary artery systolic pressure; EF – ejection
fraction.
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was the only factor that signiﬁcantly determined the cardiac
rhythm at 12 months (p = 0.023) on logistic regression analysis.
Of those who remained in SR the PCS8 and MCS8 scores were
signiﬁcantly better (p < 0.001 and p < 0.001, respectively) than
those who were in AF (Table 8).
3.4. Other ﬁndings
The improvement in New York Heart Association functional
class at 3 months was more pronounced in patients with SR
than in those with AF (p = 0.022). This was not signiﬁcantly
different at the end of 12 months. Of the 36 patients
who received amiodarone and followed up for a period of
12 months, 9 patients required dose reduction because
of sinus bradycardia in 3 (8.3%), abnormal liver function test in
2 (5.6%), clinical and subclinical hypothyroidism respectively in
2 (5.6%) and 1 (2.8%) and QT prolongation in 1 (2.8%) patient.
BMV results (Table 8) showed a signiﬁcant improvement in
mitral valve area, and reduction in LA size, pressure, mitral
gradient and pulmonary artery systolic pressure.Table 6 – Univariate analysis of parameters for remaining
in SR at 12 months.
Factors Rhythm at 12 months p value
Sinus
rhythm
Atrial
ﬁbrillation
Age (mean  SD, years) 39.45  7.899 39.14  9.469 0.884
Duration of AF
(mean  SD, months)
7.24  3.612 9.77  5.076 0.023
Pre MVA
(mean  SD, cm2)
0.91  0.152 0.87  0.195 0.355
Pre MVG
(mean  SD, mmHg)
21.45  4.239 22.34  4.057 0.369
Pre LA size
(mean  SD, cm)
4.75  0.359 4.90  0.397 0.121
Pre LA pressure
(mean  SD, mmHg)
26.76  4.257 28.59  5.087 0.113
Pre PASP
(mean  SD, mmHg)
58.66  12.30 64.20  14.32 0.091
AF – atrial ﬁbrillation; MVA – mitral valve area; MVG – mitral valve
gradient; LA – left atrium; PASP – pulmonary artery systolic
pressure.4. Discussion
Our study explored the maintenance of sinus rhythm with
amiodarone therapy following DCCV, early after successful
BMV. Hofmann et al.16 showed that IV amiodarone is effective
in restoring SR in 28% of patients with AF but in our study AF
did not convert to SR with IV amiodarone alone. In our study,
pretreatment with amiodarone did not alter the efﬁcacy of
DCCV or the energy required for restoration of SR in those
patients with persistent AF. These results were similar to those
of Channer et al. study.17
Most recurrences of AF occur within the ﬁrst 3 months of
DCCV.17 Oral prophylactic drugs are given to reduce this
recurrence rate although until recently, clear efﬁcacy data
based on controlled trials has been limited. Amiodarone may
be the most effective oral prophylaxis, although all random-
ized trials of amiodarone for long-term maintenance of SR in
patients with recurrent persistent AF have used active-control
groups. Amiodarone is more effective than class-I antiarrhyth-
mic agents, without the purported risk of increased mortality
associated with quinidine and others in this class.18,19
Amiodarone is more effective than other class III agents, with
maintenance of SR in 75% on amiodarone compared to only
37% on sotalol after a mean follow-up of 16 months in one
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open-label study has demonstrated greater efﬁcacy of amio-
darone compared to the class IV agent diltiazem at 2 months
(68% SR on amiodarone compared to 48% SR on diltiazem
180 mg daily).21 Our study demonstrated a clear beneﬁt with
amiodarone compared to placebo in the maintenance of SR at
3 months following DCCV, persisting to 12 months when
amiodarone was continued. Patients in the amiodarone group
were also found to have better quality of both physical and
mental health during the 3rd and 12th month follow-up as
assessed by SF8 QoL survey.
Randomized trials have not demonstrated any outcome
advantage to rhythm control strategies, but many patients
are symptomatic in AF despite adequate rate control, with
complaints such as palpitations, dyspnea, or poor exercise
tolerance. Such patients often feel better if SR can be
maintained. Studies that compared rhythm control and rate
control strategies have found no differences in the QoL.22–24
In contrast, among patients in whom SR is successfully
maintained, exercise capacity and QoL are improved.25
Our study also clearly demonstrated that QoL was signiﬁ-
cantly improved in patients who were restored and main-
tained in SR.
The mean age in AFFIRM and a RACE trial was 70 and 68
years, respectively. In our study, the mean age in the
amiodarone group was 38.8 years and in the placebo group
37.6 years. So in our study, the average age was much lower
than the AFFIRM and RACE trials. So younger group of patients
might beneﬁt from more aggressive rhythm control strategy.
In the AFFIRM study, the antiarrhythmic drug used to
maintain SR was left to the discretion of the treating physician
but in our study amiodarone was the only drug used. The
incidence of adverse effects was not signiﬁcant enough
warranting discontinuation of drug in patients taking amio-
darone even at 12 months in our study.
4.1. Limitations
The time course of changes in mitral valve area and LA size
was not systematically followed, as recurrence of AF may be
caused by restenosis of the mitral valve. Follow-up period was
only 1 year and serious long-term adverse side effects of
amiodarone may not have been evident.
4.2. Conclusion
Amiodarone is more effective than placebo in maintenance of
SR at the end of 3 months following successful cardioversion
and more patients continued to remain in SR even at the end of
12 months without major serious adverse effects. Weighing
the risks and beneﬁts long-term amiodarone therapy follow-
ing successful DCCV may be a preferred rhythm control
strategy. The study also concludes that by restoring and
maintaining SR; QoL scores are improved when compared with
patients in whom AF is allowed to persist.
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